54874-26-9

Usage

Uses

Used in Pharmaceutical Industry:
3-(hydroxymethyl)-2-methylphenol serves as a key starting material in the synthesis of various pharmaceuticals, most notably the antitussive drug guaifenesin. Its role in the creation of such medications underscores its importance in this sector.
Used in Flavor and Fragrance Industry:
In the flavor and fragrance industry, 3-(hydroxymethyl)-2-methylphenol is utilized as a precursor to a variety of flavor compounds. Its ability to contribute to the development of distinct scents and tastes makes it a valuable component in this domain.
Used in Food and Beverage Preservation:
Leveraging its antimicrobial properties, 3-(hydroxymethyl)-2-methylphenol is employed in the preservation of food and beverages. Its use helps maintain the freshness and safety of these products, contributing to their longevity.
Used in Medical Applications:
Within the medical field, 3-(hydroxymethyl)-2-methylphenol is applied as an expectorant to aid in the relief of respiratory conditions. Additionally, it functions as a topical antiseptic, playing a crucial role in the treatment of various skin conditions.

Upstream product

• 603-80-5 3-hydroxy 2-methylbenzoic acid 

Downstream Products

• 870062-58-1 [2-methyl-3-(pyridin-2-yloxy)-phenyl]-methanol 
• 1255206-72-4 6-bromo-3-hydroxy-2-methylbenzenemethanol 
• 1310698-28-2 Isopropyl 2-[3-(hydroxymethyl)-2-methylphenoxy]acetate 
• 1255206-69-9 5-ethenyl-4-methyl-2-benzofuran-1(3H)-one 
• 1255206-67-7 5-bromo-4-methyl-2-benzofuran-1(3H)-one 
• 1548289-28-6 (E)-4-methyl-5-(prop-1-en-1-yl)isobenzofuran-1(3H)-one 
• 1255206-75-7 1,3-dihydro-1-oxo-4-methyl-5-(2-bromoacetyl)isobenzofuran 
• 1255206-73-5 trifluoromethanesulfonic acid 4-methyl-1-oxo-1,3-dihydro-isobenzofuran-5-yl ester 
• 1194700-73-6 5-hydroxy-4-methyl-3H-isobenzofuran-1-one 
• 1255206-70-2 4-methyl-5-[2R-oxiran-2-yl]-2-benzofuran-1(3H)-one 

Relevant academic research and scientific papers

Bio- And Chemocatalysis for the Synthesis of Late Stage SAR-Enabling Intermediates for ROMK Inhibitors and MK-7145 for the Treatment of Hypertension and Heart Failure

A synthetic strategy to provide two late-stage intermediates for the synthesis of diverse analogues of ROMK inhibitors for the treatment of hypertension and heart failure is described. Key transformations include carbonylation of a bromoarene, regioselect

INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Compounds of Formula I and the pharmaceutically acceptable salts thereof are provided as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula Ia and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.

INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Disclosed are compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Inhibitors of the renal outer medullary potassium channel

This invention relates to compounds of Formula I having the following general structure: [in-line-formulae]Z1—Y1—(CH2)n1—R—(CH2)n2—Y2—Z2 [/in-line-formulae] wherein R

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis